Someone gets a stroke in the United States every 40 seconds. Strokes are the third most common cause of death and disability in the world, and millions of dollars are spent each year on long-term care, rehabilitation, and support for stroke survivors. Long-term rehabilitation can be time-consuming and intensive, and conventional stroke treatments frequently fail. In other words, the time is right for a novel approach to stroke treatment and recovery.
Dimethyltryptamine, also known as DMT, is a hallucinogenic tryptamine found naturally in various plants and animals. Due to the potent psychedelic effects, some call it the “spirit molecule.” Dimethyltryptamine (DMT), regarded as the most potent psychoactive substance in the world by researchers and psychedelic adventurers, appears to be altering the paradigm of consciousness.
According to Dr. David Nutt, professor of neuropsychopharmacology at Imperial College London and consultant for Algernon, “hundreds of medications have failed in the stroke treatment area, and nearly all of them have concentrated on the same strategy: a delayed attempt at neuroprotection.”
“Algernon uses DMT to support the brain’s natural recuperation process by promoting neuroplasticity to aid in the development of new neural networks. This is a whole new approach from what has previously been tried.”
While less well-known than other psychedelics like LSD or magic mushrooms, DMT provides a brief but intense visual and audio hallucinatory experience.
According to Christopher Moreau, CEO of Algernon, “In a rat stroke occlusion research, rats given DMT demonstrated reduction in the region of brain damage from the stroke and had practically a full recovery of motor function when compared to controls.” “DMT boosted neuroplasticity in a cortical neuron development assay in a preclinical research study at UC Davis.”
The trial, which they are conducting at the Centre for Human Drug Research (CHDR) in Leiden, aims to decide the safety, tolerability, and pharmacokinetics of DMT when given as an intravenous bolus followed by a prolonged infusion for lengths that, according to the Company, have never been clinically studied.